User login
Dexamethasone-associated posterior reversible encephalopathy syndrome
Article Type
              
          Changed
              Fri, 01/04/2019 - 11:13
          Display Headline
              Dexamethasone-associated posterior reversible encephalopathy syndrome
          Posterior reversible encephalopathy syndrome (PRES) can be correlated with medical illness, hypertension, and treatment with medications that cause immunosuppression. This syndrome was first described by Hinchey and colleagues in 1996. PRES is not necessarily confined to the posterior white matter of the brain as the name indicates, but can be located in the frontal lobes, basal ganglia, cortex, and brain stem. Manifestations of this syndrome include seizures, headache, visual loss, altered mental status, visual changes, and radiologic alterations, and are easily detected on magnetic-resonance imaging (MRI) of the brain.
Click on the PDF icon at the top of this introduction to read the full article. 
Article PDF
              
          Issue
              The Journal of Community and Supportive Oncology - 14(9)
          Page Number
              392-393
          Legacy Keywords
              posterior reversible encephalopathy syndrome, PRES, brain, neuroendocrine tumor, esophagus
          Sections
          
      Article PDF
              
          Article PDF
              
          Posterior reversible encephalopathy syndrome (PRES) can be correlated with medical illness, hypertension, and treatment with medications that cause immunosuppression. This syndrome was first described by Hinchey and colleagues in 1996. PRES is not necessarily confined to the posterior white matter of the brain as the name indicates, but can be located in the frontal lobes, basal ganglia, cortex, and brain stem. Manifestations of this syndrome include seizures, headache, visual loss, altered mental status, visual changes, and radiologic alterations, and are easily detected on magnetic-resonance imaging (MRI) of the brain.
Click on the PDF icon at the top of this introduction to read the full article. 
Posterior reversible encephalopathy syndrome (PRES) can be correlated with medical illness, hypertension, and treatment with medications that cause immunosuppression. This syndrome was first described by Hinchey and colleagues in 1996. PRES is not necessarily confined to the posterior white matter of the brain as the name indicates, but can be located in the frontal lobes, basal ganglia, cortex, and brain stem. Manifestations of this syndrome include seizures, headache, visual loss, altered mental status, visual changes, and radiologic alterations, and are easily detected on magnetic-resonance imaging (MRI) of the brain.
Click on the PDF icon at the top of this introduction to read the full article. 
Issue
              The Journal of Community and Supportive Oncology - 14(9)
          Issue
              The Journal of Community and Supportive Oncology - 14(9)
          Page Number
              392-393
          Page Number
              392-393
          Article Type
              
          Display Headline
              Dexamethasone-associated posterior reversible encephalopathy syndrome
          Display Headline
              Dexamethasone-associated posterior reversible encephalopathy syndrome
          Legacy Keywords
              posterior reversible encephalopathy syndrome, PRES, brain, neuroendocrine tumor, esophagus
          Legacy Keywords
              posterior reversible encephalopathy syndrome, PRES, brain, neuroendocrine tumor, esophagus
          Sections
          
      Citation Override
              JCSO 2016;14(9)392-39
          Disallow All Ads
              
          Alternative CME
              
          Article PDF Media
              Document
              
          Media Folder